SG11202004698RA - Process for the preparation of drug linker compounds - Google Patents
Process for the preparation of drug linker compoundsInfo
- Publication number
- SG11202004698RA SG11202004698RA SG11202004698RA SG11202004698RA SG11202004698RA SG 11202004698R A SG11202004698R A SG 11202004698RA SG 11202004698R A SG11202004698R A SG 11202004698RA SG 11202004698R A SG11202004698R A SG 11202004698RA SG 11202004698R A SG11202004698R A SG 11202004698RA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- drug linker
- linker compounds
- compounds
- drug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593104P | 2017-11-30 | 2017-11-30 | |
| PCT/US2018/063070 WO2019108797A1 (en) | 2017-11-30 | 2018-11-29 | Process for the preparation of drug linker compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004698RA true SG11202004698RA (en) | 2020-06-29 |
Family
ID=66665808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004698RA SG11202004698RA (en) | 2017-11-30 | 2018-11-29 | Process for the preparation of drug linker compounds |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11612666B2 (de) |
| EP (1) | EP3717016A4 (de) |
| JP (2) | JP7402159B2 (de) |
| KR (1) | KR20200094185A (de) |
| CN (2) | CN111417408B (de) |
| AU (1) | AU2018375412A1 (de) |
| BR (1) | BR112020010503A2 (de) |
| CA (1) | CA3082165A1 (de) |
| EA (1) | EA202091340A1 (de) |
| IL (1) | IL274757A (de) |
| MA (1) | MA51870A (de) |
| MX (2) | MX2020005565A (de) |
| SG (1) | SG11202004698RA (de) |
| WO (1) | WO2019108797A1 (de) |
| ZA (1) | ZA202003037B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020233174A1 (zh) * | 2019-05-20 | 2020-11-26 | 烟台迈百瑞国际生物医药有限公司 | 一种抗体药物偶联物中间体的一锅法制备工艺 |
| AU2019284038B1 (en) * | 2019-10-23 | 2021-01-07 | Mabplex International Co., Ltd. | Oligopeptide linker intermediate and preparation method thereof |
| EP4308170A1 (de) | 2021-03-18 | 2024-01-24 | Seagen Inc. | Selektive wirkstofffreisetzung aus internalisierten konjugaten biologisch aktiver verbindungen |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| BR122018071808B8 (pt) * | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| ES2382879T3 (es) | 2005-09-14 | 2012-06-14 | Ucb Pharma, S.A. | Conjugado de anticuerpo - polímero de peine. |
| BRPI0716812A2 (pt) | 2006-09-15 | 2013-11-05 | Enzon Pharmaceuticals Inc | Pro drogas polimericas direcionadas contendo ligantes multifuncionais |
| JP5358566B2 (ja) | 2007-06-21 | 2013-12-04 | アムジエン・インコーポレーテツド | シナカルセトおよびその塩を合成する方法 |
| EA201391756A1 (ru) | 2011-05-27 | 2014-05-30 | Амбркс, Инк. | Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами |
| CN104640572B (zh) * | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| LT3418281T (lt) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
| GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| GB201416960D0 (en) * | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
| US9533483B2 (en) | 2014-09-26 | 2017-01-03 | Kimberly-Clark Worldwide, Inc. | Apparatus for and method of shaping and applying a segment to a moving web |
-
2018
- 2018-11-29 AU AU2018375412A patent/AU2018375412A1/en active Pending
- 2018-11-29 MX MX2020005565A patent/MX2020005565A/es unknown
- 2018-11-29 SG SG11202004698RA patent/SG11202004698RA/en unknown
- 2018-11-29 KR KR1020207018586A patent/KR20200094185A/ko not_active Application Discontinuation
- 2018-11-29 JP JP2020529321A patent/JP7402159B2/ja active Active
- 2018-11-29 BR BR112020010503-1A patent/BR112020010503A2/pt unknown
- 2018-11-29 EA EA202091340A patent/EA202091340A1/ru unknown
- 2018-11-29 CN CN201880077478.0A patent/CN111417408B/zh active Active
- 2018-11-29 CA CA3082165A patent/CA3082165A1/en active Pending
- 2018-11-29 US US16/768,027 patent/US11612666B2/en active Active
- 2018-11-29 CN CN202410349991.8A patent/CN118271394A/zh active Pending
- 2018-11-29 MA MA051870A patent/MA51870A/fr unknown
- 2018-11-29 EP EP18883925.2A patent/EP3717016A4/de active Pending
- 2018-11-29 WO PCT/US2018/063070 patent/WO2019108797A1/en unknown
-
2020
- 2020-05-18 IL IL274757A patent/IL274757A/en unknown
- 2020-05-22 ZA ZA2020/03037A patent/ZA202003037B/en unknown
- 2020-07-13 MX MX2023009372A patent/MX2023009372A/es unknown
-
2023
- 2023-01-31 US US18/162,432 patent/US20240042052A1/en active Pending
- 2023-09-20 JP JP2023152281A patent/JP2023164652A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019108797A1 (en) | 2019-06-06 |
| JP2021505542A (ja) | 2021-02-18 |
| EA202091340A1 (ru) | 2020-10-16 |
| ZA202003037B (en) | 2023-12-20 |
| MX2020005565A (es) | 2020-08-20 |
| CA3082165A1 (en) | 2019-06-06 |
| CN111417408A (zh) | 2020-07-14 |
| JP2023164652A (ja) | 2023-11-10 |
| US20200360532A1 (en) | 2020-11-19 |
| BR112020010503A2 (pt) | 2020-10-20 |
| AU2018375412A1 (en) | 2020-05-28 |
| IL274757A (en) | 2020-07-30 |
| EP3717016A1 (de) | 2020-10-07 |
| CN111417408B (zh) | 2024-04-23 |
| MA51870A (fr) | 2020-10-07 |
| CN118271394A (zh) | 2024-07-02 |
| EP3717016A4 (de) | 2021-09-01 |
| US20240042052A1 (en) | 2024-02-08 |
| US11612666B2 (en) | 2023-03-28 |
| JP7402159B2 (ja) | 2023-12-20 |
| KR20200094185A (ko) | 2020-08-06 |
| MX2023009372A (es) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265239A (en) | A process for the production of a solid pharmaceutical preparation | |
| ZA201706795B (en) | Process for the preparation of dicycloplatin | |
| GB201709652D0 (en) | Pharmaceutical compounds | |
| GB201704965D0 (en) | Pharmaceutical compounds | |
| GB201704714D0 (en) | Pharmaceutical compounds | |
| GB201703881D0 (en) | Pharmaceutical compounds | |
| IL267508B (en) | A process for the preparation of 2-pyridylethyl carboxamide derivatives | |
| IL260465B (en) | A process for preparing an antibody-rifamycin conjugate | |
| IL274757A (en) | A process for preparing drug binding compounds | |
| GB201706806D0 (en) | Pharmaceutical compounds | |
| IL268835B (en) | A process for the preparation of 2-cyanoimidazole compounds | |
| GB201704966D0 (en) | Pharmaceutical compounds | |
| IL275480A (en) | A process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| IL275381A (en) | A process for the preparation of Crisborole | |
| ZA202002116B (en) | Process for the preparation of piperine | |
| HRP20181918T1 (hr) | Postupak za sintezu derivata benzazepina | |
| HRP20220427T8 (hr) | Farmaceutski spojevi | |
| GB201711704D0 (en) | Pharmaceutical compounds | |
| IL274560A (en) | A process for the preparation of raltagravir | |
| HK1252354A1 (zh) | 製備兩親性咪唑啉鎓化合物的方法 | |
| HK1258181A1 (zh) | 製備螯合劑的方法 | |
| GB201717005D0 (en) | Pharmaceutical compounds | |
| GB201700867D0 (en) | Pharmaceutical compounds |